These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11876899)

  • 1. [Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase].
    Wang H; Peng Y; Xiao G
    Zhonghua Shao Shang Za Zhi; 2000 Dec; 16(6):349-51. PubMed ID: 11876899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
    Singlas E
    Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
    Chan CY; Lai KN; Lam AW; Li PK; Chung WW; French GL
    J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
    Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
    Keller E; Fecht H; Böhler J; Schollmeyer P
    Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis.
    Bergan T; Michalsen H; Malmborg AS; Pedersen SS; Pressler T; Storrøsten OT; Strandvik B
    Chemotherapy; 1993; 39(6):369-73. PubMed ID: 8222862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
    Janmohamed RM; Leyland MJ; Kelly J; Farrell I
    J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
    Vos MC; Vincent HH; Yzerman EP
    Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
    Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
    Tegeder I; Bremer F; Oelkers R; Schobel H; Schüttler J; Brune K; Geisslinger G
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
    Pietroski NA; Graziani AL; Lawson LA; Bland JA; Rogers JD; MacGregor RR
    Antimicrob Agents Chemother; 1991 May; 35(5):972-5. PubMed ID: 1854179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
    Alarabi AA; Cars O; Danielson BG; Salmonson T; Wikström B
    J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem pharmacokinetics in patients with burns.
    Boucher BA; Hickerson WL; Kuhl DA; Bombassaro AM; Jaresko GS
    Clin Pharmacol Ther; 1990 Aug; 48(2):130-7. PubMed ID: 2379384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of imipenem in burn patients.
    Dailly E; Kergueris MF; Pannier M; Jolliet P; Bourin M
    Fundam Clin Pharmacol; 2003 Dec; 17(6):645-50. PubMed ID: 15015709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using imipenem and cilastatin during continuous renal replacement therapy.
    Cotton A; Franklin BD; Brett S; Holmes A
    Pharm World Sci; 2005 Oct; 27(5):371-5. PubMed ID: 16341743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life.
    Reed MD; Kliegman RM; Yamashita TS; Myers CM; Blumer JL
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1172-7. PubMed ID: 2393278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
    Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.
    Hashimoto S; Honda M; Yamaguchi M; Sekimoto M; Tanaka Y
    ASAIO J; 1997; 43(1):84-8. PubMed ID: 9116359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.